🔥🐔 BizChicken 🐔🔥

Companies Similar to Biohaven Pharmaceutical Holding Company Ltd.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

DNAbilize

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.

Tags: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, DNAbilize, Drug Development, Lymphoma, Myelodysplastic Syndrome, Oncology, Pancreatic Cancer, Prexigebersen, RNAi

Symbol: BPTH

Recent Price: $1.17

Industry: Biotechnology

CEO: Mr. Peter H. Nielsen MBA

Sector: Healthcare

Employees: 10

Address: 4710 Bellaire Boulevard, Bellaire, TX 77401

Phone: 832 742 1357

Leadership

  • Peter Nielsen, Chief Executive Officer, Chief Financial Officer
  • Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
  • Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
  • Michael Hickey, MBA, Vice President of Clinical Operations
  • Michael Roberts, Director of Manufacturing Planning & Engineering
  • Chairman of the Board,
  • President,
  • Heath Cleaver, Director
  • Paul Aubert, Director
  • Douglas P. Morris, Director
  • Aline Sherwood, Director

Last updated: 2024-12-31

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Aytu BioPharma, Inc.

Aytu BioPharma, Inc. logo
Market Cap: Lowest
Employees: Low

Adzenys XR-ODT

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics and consumer healthcare products in the United States and internationally. They offer products for the treatment of ADHD, allergies, fluoride deficiency, cough, and insomnia.

Tags: ADHD, Allergies, Fluoride Deficiency, Healthcare, Insomnia, Pharmaceuticals, Therapeutics

Symbol: AYTU

Recent Price: $1.61

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Joshua R. Disbrow

Sector: Healthcare

Employees: 102

Address: 373 Inverness Parkway, Englewood, CO 80112

Phone: 720 437 6580

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. logo
Market Cap: Highest
Employees: High

Vimizim

Bio Marin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Their products cater to conditions like mucopolysaccharidosis, phenylketonuria, Batten disease, and more.

Tags: biotechnology, enzyme replacement therapy, healthcare, pharmaceutical, rare diseases

Symbol: BMRN

Recent Price: $65.45

Industry: Biotechnology

CEO: Mr. Alexander Hardy

Sector: Healthcare

Employees: 3401

Address: 770 Lindaro Street, San Rafael, CA 94901

Phone: 415 506 6700

Leadership

  • Mark Enyedy,
  • Alexander Hardy,
  • Elaine J. Heron,
  • G. Eric Davis, Executive Vice President, Chief Legal Officer
  • Greg Friberg, Executive Vice President, Chief Research & Development Officer
  • C. Greg Guyer, Executive Vice President, Chief Technical Officer
  • Cristin Hubbard, Executive Vice President, Chief Commercial Officer
  • Marni Kottle, Executive Vice President, Chief Corporate Affairs Officer
  • Brian R. Mueller, Executive Vice President, Chief Financial Officer
  • James Sabry, Executive Vice President, Chief Business Officer
  • Amy Wireman, Executive Vice President, Chief People Officer
  • Richard A. Meier,
  • Elizabeth McKee Anderson,
  • Barbara Bodem,
  • Athena Countouriotis,
  • Willard H. Dere,
  • Maykin Ho,
  • Robert J. Hombach,
  • David E.I. Pyott,

Last updated: 2024-12-31

Benitec Biopharma Inc.

Benitec Biopharma Inc. logo
Market Cap: Low
Employees: Lowest

BB-301 and BB-103

Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference-based therapeutics for chronic and life-threatening conditions. Its lead products include BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.

Tags: RNA interference, biotechnology, chronic conditions, gene therapy, genetic medicines, hepatitis B, oculopharyngeal muscular dystrophy

Symbol: BNTC

Recent Price: $12.51

Industry: Biotechnology

CEO: Dr. Jerel A. Banks M.D., Ph.D.

Sector: Healthcare

Employees: 16

Address: 3940 Trust Way, Hayward, CA 94545

Phone: 510 780 0819

Leadership

  • Jerel Banks, M.D., Ph.D., Chief Executive Officer & Chairman of the Board
  • Megan Boston, Executive Director

Last updated: 2024-12-31

biote Corp.

biote Corp. logo
Market Cap: Low
Employees: Low

Biote platform

biote Corp. operates in the hormone optimization space, offering a platform for Biote-certified practitioners to manage hormone imbalances and prescribe therapies. The company sells Biote-branded supplements and pellet insertion kits.

Tags: bioidentical therapies, dietary supplements, hormone optimization, medical practice

Symbol: BTMD

Recent Price: $5.91

Industry: Medical - Care Facilities

CEO: Ms. Teresa S. Weber

Sector: Healthcare

Employees: 194

Address: 1875 West Walnut Hill Lane, Irving, TX 75038

Phone: 844-604-1246

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Organovo Holdings, Inc.

Organovo Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Novo Gen Bioprinters

Organovo Holdings, Inc. is a biotechnology company that develops 3D tissues to model human diseases, utilizing proprietary bioprinting technologies such as Novo Gen Bioprinters for fabricating living tissues.

Tags: 3D tissues, Ex Vive, Novo Gen Bioprinters, bioprinting, biotechnology, human disease

Symbol: ONVO

Recent Price: $0.36

Industry: Biotechnology

CEO: Mr. Keith E. Murphy

Sector: Healthcare

Employees: 20

Address: 11555 Sorrento Valley Road, Solana Beach, CA 92121

Phone: 858 224 1000

Leadership

  • Keith Murphy, Executive Chairman, CEO
  • Thomas P. Hess, Chief Financial Officer
  • Curtis Tyree, Ph.D., Senior Vice President, Strategy and Business Development
  • Adam K. Stern, CEO
  • Alison Milhous, Vice President, Accounting
  • David Gobel, CEO
  • Doug Cohen, President and Chief Executive Officer
  • Vaidehi Joshi, Director of Discovery Biology

Last updated: 2024-12-31

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

OV101, OV329, OV350, OV882, OV815

Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.

Tags: biopharmaceutical, clinical trials, medicine development, neurological disorders

Symbol: OVID

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Sector: Healthcare

Employees: 40

Address: 1460 Broadway, New York, NY 10036

Phone: 646 661 7661

Leadership

  • Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
  • Meg Alexander, President and Chief Operating Officer
  • Zhong Zhong, Ph.D., Chief Scientific Officer
  • Jeffrey Rona, Chief Business and Financial Officer
  • Amanda Banks, M.D., Chief Development Officer
  • Julia Tsai, Ph.D., Senior Vice President of Clinical Development
  • Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
  • Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
  • Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
  • Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
  • Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. logo
Market Cap: Low
Employees: Low

Rani Pill

Rani Therapeutics Holdings, Inc. is a clinical stage biotherapeutics company focused on developing orally administered biologics with its Rani Pill platform, aimed at replacing subcutaneous or IV injections. The company has multiple products in various stages of development targeting conditions like neuroendocrine tumors, psoriatic arthritis, osteoporosis, growth hormone deficiency, hypoparathyroidism, and type 2 diabetes.

Tags: Rani Pill, biologics, biotherapeutics, clinical trials, healthcare, pharmaceuticals

Symbol: RANI

Recent Price: $1.48

Industry: Biotechnology

CEO: Mr. Talat Imran

Sector: Healthcare

Employees: 140

Address: 2051 Ringwood Avenue, San Jose, CA 95131

Phone: 408 457 3700

Leadership

  • Talat Imran, Chief Executive Officer
  • Mir Imran, Founder and Executive Chairman
  • Mir Hashim, Chief Scientific Officer
  • Svai Sanford, Chief Financial Officer
  • Eric Groen, General Counsel
  • Kate McKinley, Chief Business Officer
  • Jacques Van Dam, Vice President, Medical Affairs
  • Alireza Javadi, VP of Technical Operations
  • Betsy Gutierrez, Vice President, Quality Assurance
  • Bella Vazquez, Vice President, Human Resources
  • Kyle Horlen, VP of Nonclinical Development & Safety Assessment
  • Arvinder Dhalla, Vice President, Clinical Development
  • Andrew Farquharson, Managing Director, VHM and InCube Ventures
  • Maulik Nanavaty, CEO of Anumana
  • Jean-Luc Butel, Director at Takeda, Novo Holdings, and SG Innovate
  • Laureen DeBuono, Managing Partner, FLG Partners
  • Dennis Ausiello, Director of CATCH & Former Chief of Medicine, Mass General
  • Lisa Rometty, President, CVS Kidney Care

Last updated: 2024-12-31

Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

SON-1010, SON-080

Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.

Tags: albumin binding technology, biologic medicines, biotechnology, interleukin 12, interleukin 6, oncology

Symbol: SONN

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Pankaj Mohan Ph.D.

Sector: Healthcare

Employees: 12

Address: 100 Overlook Center, Princeton, NJ 08540

Phone: 609-375-2227

Leadership

  • Pankaj Mohan, Ph.D., Founder, CEO & Chairman
  • Jay Cross, Chief Financial Officer
  • John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
  • Susan Dexter, Chief Technical Officer
  • Richard Kenney, M.D., Chief Medical Officer
  • Albert Dyrness, Board Member
  • Nailesh Bhatt, Chief Executive Officer & Board Member
  • Raghu Rao, Board Member
  • Donald Griffith, Financial Controller
  • Lori McNeill, Board Member

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Annovis Bio, Inc.

Annovis Bio, Inc. logo
Market Cap: Low
Employees: Lowest

Buntanetap

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound, Buntanetap, is in clinical trials for various neurodegenerative disorders.

Tags: Alzheimer's disease, Parkinson's disease, clinical trials, drug development, neurodegeneration

Symbol: ANVS

Recent Price: $5.08

Industry: Biotechnology

CEO: Dr. Maria L. Maccecchini Ph.D.

Sector: Healthcare

Employees: 6

Address: 1055 Westlakes Drive, Berwyn, PA 19312

Phone: 610 727 3913

Last updated: 2024-12-31

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd. logo
Market Cap: High
Employees: Low

NURTEC ODT (rimegepant)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops product candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States.

Tags: biopharmaceutical, migraine treatment, neurological diseases, neuropsychiatric disorders, rare disorders

Symbol: BHVN

Recent Price: $35.78

Industry: Biotechnology

CEO: Dr. Vladimir Coric M.D.

Sector: Healthcare

Employees: 239

Address: 215 Church Street, New Haven, CT 06510

Phone: 203 404 0410

Last updated: 2024-12-31

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renazorb, UNI 494

Unicycive Therapeutics is a biotech company developing novel therapies for kidney diseases in the United States, focusing on treatments for hyperphosphatemia and acute kidney injury.

Tags: Renazorb, UNI 494, acute kidney injury, biotechnology, hyperphosphatemia, kidney diseases

Symbol: UNCY

Recent Price: $0.58

Industry: Biotechnology

CEO: Dr. Shalabh K. Gupta M.D., MPA

Sector: Healthcare

Employees: 14

Address: 4300 El Camino Real, Los Altos, CA 94022

Phone: 650 351 4495

Last updated: 2024-11-08

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31